Cytokine News and Research

RSS

Machine learning approach to identify drugs that could be repurposed to fight Covid-19

When the Covid-19 pandemic struck in early 2020, doctors and researchers rushed to find effective treatments.

16 Feb 2021

Electrochemical sensor for rapid detection of multiple sepsis biomarkers in whole blood

Many life-threatening medical conditions, such as sepsis, which is triggered by blood-borne pathogens, cannot be detected accurately and quickly enough to initiate the right course of treatment.

15 Feb 2021

Mast Cells: High-speed messengers of the immune defense

In order to fight pathogens, mast cells regulate inflammatory reactions of the immune system.

10 Feb 2021

Study reveals genetic factors linked to COVID-19 susceptibility in people with Down syndrome

A study reveals the genetic factors that may expose or protect people with Down syndrome from SARS-CoV-2 infection, as well as the prognosis of COVID-19.

9 Feb 2021

Breast cancer-on-a-chip for rapid screening of immunotherapeutic drugs

There are many mechanisms by which the body responds to foreign invaders. One of these involves the T-cells of the immune system, which have a number of different proteins on their surface called "checkpoint proteins."

3 Feb 2021

Noncoding RNA plays key role in sepsis, regulates inflammatory gene expression

Sepsis can result when the body’s immune response to a specific infection gets out of control.

2 Feb 2021

Non-steroidal anti-inflammatory drugs reduce antibody and inflammatory responses to COVID-19

According to a new study, non-steroidal anti-inflammatory drugs (NSAIDs) decreased both inflammatory and antibody responses to SARS-CoV-2 infection in mice.

26 Jan 2021

Gene therapy helps paralyzed mice to walk again

For the first time, scientists have successfully used gene therapy to make mice walk again after these animals suffered a complete cross-sectional injury.

18 Jan 2021

Researchers create molecular ON-OFF switches to regulate CAR T cell activity

CAR T cells are a breakthrough class of effective but often toxic cancer therapies. To prevent overactivation, switchable CAR T cells were engineered that can be turned on and off with an approved, widely used cancer drug.

7 Jan 2021

Sugar-binding protein could serve as a useful biomarker for patients at risk of sepsis

According to a research team headed by the University of Connecticut Health, a sugar-binding protein could drive terrible inflammation and worsen sepsis—a disease that kills over 270,000 individuals per year in the United States alone.

5 Jan 2021

Gut cells raise alarm during parasite invasion

To effectively combat an infection, the body first has to sense it's been invaded, then the affected tissue must send out signals to corral resources to fight the intruder.

29 Dec 2020

Kobe University and Sysmex conduct joint research on new blood test for identifying COVID-19

Kobe University and Sysmex Corporation have been engaged in joint research on the ELISPOT method, a new blood test for identifying the novel coronavirus disease (COVID-19).

28 Dec 2020

New analysis technique could pave way for major breakthroughs in immunotherapy

In a new study, researchers at Uppsala University have been able to show differences in how Rituximab, a monoclonal antibody drug, interacts with the blood of healthy individuals compared to patients with chronic lymphatic leukaemia.

14 Dec 2020

Study: CAR T cell therapy is a safe, effective therapy for high-risk large B-cell lymphoma

A study led by researchers at The University of Texas MD Anderson Cancer Center found that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma (LBCL), a group with an urgent need for new and effective treatments.

8 Dec 2020

CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.

7 Dec 2020

Subcutaneous injection of teclistamab drug shows promise in treating aggressive multiple myeloma

A subcutaneous injection of the immune-boosting drug teclistamab was found to be safe and elicit responses in a majority of patients with relapsed or refractory multiple myeloma, according to findings from a multi-institutional phase I study being presented by Alfred L. Garfall, MD, an assistant professor of Medicine in the division of Hematology-Oncology in the Perelman School of Medicine at the University of Pennsylvania, at the annual American Society of Hematology & Exposition Meeting on Dec. 5 (abstract #180).

7 Dec 2020

Disturbances in the gut microbiome may explain major depressive disorder

Researchers have successfully detected three bacteriophages, 50 fecal metabolites, 47 bacterial species that were considerably more or less abundant in patients with major depressive disorder (MDD) when compared to healthy controls. The study involved 311 individuals.

4 Dec 2020

First functional analysis of cytokine IL-15L using rainbow trout

The cytokine family including interleukin-2 and -15 (IL-2 and IL-15) started out in a primitive vertebrate species with three related cytokines IL-2, IL-15, and IL-15-like (IL-15L), all sharing binding capacity for receptor chain IL-15Rα. IL-15L was conserved in fishes, reptiles, and some mammals but lost in humans and mice.

23 Nov 2020

Adipose tissue plays key role in the aggravation of COVID-19

There is growing evidence that adipose tissue plays a key role in the aggravation of COVID-19. One of the theories under investigation is that fat cells (adipocytes) act as a reservoir for SARS-CoV-2 and increase viral load in obese or overweight individuals.